Form 4: Assertio COO Schwichtenberg's Stock Holdings Update

Assertio Holdings' President and COO, Paul Schwichtenberg, reported the vesting and settlement of restricted stock units, along with shares withheld for tax obligations.

Summary

• Paul Schwichtenberg, President and COO of Assertio Holdings, Inc., reported transactions related to his beneficial ownership.
• On February 7, 2026, 1,666 restricted stock units (RSUs) vested and were converted into common stock.
• Concurrently, 825 shares of common stock were withheld to cover tax obligations related to the RSU vesting, at a price of $12.74 per share.
• Following these transactions, Schwichtenberg directly owns 12,009 shares of Assertio Holdings common stock.
• He also beneficially owns 1,667 derivative securities (Restricted Stock Units) which are scheduled to vest on February 7, 2027.
• All reported share amounts have been adjusted to reflect a 1-for-15 reverse stock split effected on December 26, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, indicating continued alignment of the COO's interests with the company's performance, with no significant positive or negative implications beyond standard operations.

Positives

• Vesting of restricted stock units indicates continued employment and alignment of management interests with shareholders.
• The conversion of RSUs to common stock increases the COO's direct equity stake in the company (though some were withheld for tax).

Negatives

• A portion of the vested shares (825 shares) was sold/withheld to cover tax liabilities, reducing the net increase in direct ownership.

Future Outlook

The remaining 1,667 restricted stock units held by Paul Schwichtenberg are scheduled to vest on February 7, 2027, assuming his continued employment.

Industry Context

StockSavvy.ai notes that the vesting and tax-related disposition of restricted stock units are standard compensation practices for executives in the pharmaceutical and biotechnology industries, aligning executive incentives with long-term company performance. This filing provides a routine update on an executive's equity holdings, typical for a company like Assertio Holdings, which operates in a competitive and innovation-driven sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across various industries, including pharmaceuticals. Companies such as Pfizer, Johnson & Johnson, and Merck frequently utilize similar equity-based incentives to retain key talent and align executive interests with shareholder value creation.
• The 1-for-15 reverse stock split, while not directly comparable to RSU vesting, is a corporate action sometimes undertaken by companies to meet listing requirements or improve stock perception, as seen with other smaller-cap biotech firms.

Stakeholder Impact

• Shareholders: The COO's continued equity ownership aligns his interests with shareholders. The tax withholding is a routine event.
• Employees: No direct impact on general employees.

Next Steps

• The remaining 1,667 restricted stock units are scheduled to vest on February 7, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax withholding) and does not contain information that would fundamentally alter the investment thesis for Assertio Holdings. It confirms the COO's continued equity stake and alignment but offers no new operational or financial data to warrant a change in investment posture.

Keywords

Assertio Holdings, ASRT, Paul Schwichtenberg, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Ownership, Corporate Officer, Reverse Stock Split